Results 91 to 100 of about 198,722 (342)
Overview of molecular signatures of senescence and associated resources: pros and cons
FEBS Open Bio, EarlyView.Cells can enter a stress response state termed cellular senescence that is involved in various diseases and aging. Detecting these cells is challenging due to the lack of universal biomarkers. This review presents the current state of senescence identification, from biomarkers to molecular signatures, compares tools and approaches, and highlights ...
Orestis A. Ntintas +6 more
wiley +1 more source
BRAF Mutation Heterogeneity in Melanoma Lesions
Acta Dermato-Venereologica, 2020 is missing (Short communication)
Kaori Sakaizawa +3 more
doaj +1 more source
Metastases risk in thin cutaneous melanoma: Prognostic value of clinical-pathologic characteristics and mutation profile [PDF]
, 2018 Background: A high percentage of patients with thin melanoma (TM), defined as lesions with Breslow thickness ≤1 mm, presents excellent long-term survival, however, some patients develop metastases.
Calvieri, Stefano +12 more
core +1 more source
BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
Cancers, 2020 The BRAF inhibitors vemurafenib, dabrafenib and encorafenib are used in the treatment of patients with BRAF-mutant melanoma. They selectively target BRAF kinase and thus interfere with the mitogen-activated protein kinase (MAPK) signalling pathway that ...
I. Proietti +13 more
semanticscholar +1 more source
FEBS Open Bio, EarlyView.A novel signature integrating genome‐wide analysis with clinical factors predicts recurrence in stage II colorectal cancer and enables a new risk stratification to guide postoperative adjuvant chemotherapy. Clinical risk stratification for postoperative recurrence in patients with pathological stage II (pStage II) colorectal cancer (CRC) is essential ...
Mayuko Otomo +7 more
wiley +1 more source
The miR-139-5p regulates proliferation of supratentorial paediatric low-grade gliomas by targeting the PI3K/AKT/mTORC1 signalling [PDF]
, 2018 Paediatric low-grade gliomas (pLGGs) are a heterogeneous group of brain tumours associated with a high overall survival: however, they are prone to recur and supratentorial lesions are difficult to resect, being associated with high percentage of disease
Antonelli, Manila +19 more
core +1 more source
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma [PDF]
Case Reports in Oncology, 2019 Approximately 50% of patients with metastatic melanoma harbor an activating BRAF mutation. Tumors with activating mutation <i>BRAF</i> gene proliferate excessively and can be treated with targeted BRAF-inhibitors in combination with MEK inhibitors. The most common BRAF mutation occurs at amino acid position 600. Other <i>BRAF</i>
Sara Bjursten +7 more
openaire +3 more sources
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Glioma recurrence severely impacts patient prognosis, with current treatments showing limited efficacy. Traditional methods struggle to analyze recurrence mechanisms due to challenges in assessing tumor heterogeneity, spatial dynamics, and gene networks.
Lei Qiu +10 more
wiley +1 more source
Клиническая и экспериментальная тиреоидология, 2020 Autophagy is an important intracellular process that supports cell death and survival. Oncogenesis is associated with a change in the AKT/mTOR signaling pathway status.
Liudmila V. Spirina +3 more
doaj +1 more source
Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]
, 2018 The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Bye, Alex P. +6 more
core +4 more sources